FDA granted Fast Track designation for NSCLC treatment, while MAIA entered a master clinical supply agreement with Roche, leading to international trial expansion.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Fast Track designation for NSCLC treatment, while MAIA entered a master clinical supply agreement with Roche, leading to international trial expansion.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- MAIA Biotechnology began clinical trials, dosing the first patient in Taiwan and screening in Europe and Asia, with Regeneron providing Libtayo.Sub-event
MAIA received Fast Track designation from the FDA for NSCLC treatment and expanded trials into Europe.1 source
Keep exploring
The entities involved
- FDA
-
Hoffmann-La Roche
Swiss healthcare company
Related events
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- FDA granted Fast Track designation to NRX-100 on September 4, 2025.
Coverage
Newest first; wire copies grouped- GlobeNewswireDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) New York, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus